EP1640006A4 - Particules a liberation prolongee de medicament et procede de production de celles-ci - Google Patents

Particules a liberation prolongee de medicament et procede de production de celles-ci

Info

Publication number
EP1640006A4
EP1640006A4 EP04746293A EP04746293A EP1640006A4 EP 1640006 A4 EP1640006 A4 EP 1640006A4 EP 04746293 A EP04746293 A EP 04746293A EP 04746293 A EP04746293 A EP 04746293A EP 1640006 A4 EP1640006 A4 EP 1640006A4
Authority
EP
European Patent Office
Prior art keywords
relase
particles
producing
same
sustained drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04746293A
Other languages
German (de)
English (en)
Other versions
EP1640006A1 (fr
Inventor
Yuso Tomohira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP1640006A1 publication Critical patent/EP1640006A1/fr
Publication of EP1640006A4 publication Critical patent/EP1640006A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP04746293A 2003-06-27 2004-06-17 Particules a liberation prolongee de medicament et procede de production de celles-ci Withdrawn EP1640006A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003184040 2003-06-27
PCT/JP2004/008824 WO2005000312A1 (fr) 2003-06-27 2004-06-17 Particules a liberation prolongee de medicament et procede de production de celles-ci

Publications (2)

Publication Number Publication Date
EP1640006A1 EP1640006A1 (fr) 2006-03-29
EP1640006A4 true EP1640006A4 (fr) 2012-04-04

Family

ID=33549598

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04746293A Withdrawn EP1640006A4 (fr) 2003-06-27 2004-06-17 Particules a liberation prolongee de medicament et procede de production de celles-ci

Country Status (14)

Country Link
US (1) US8734843B2 (fr)
EP (1) EP1640006A4 (fr)
JP (1) JP4592590B2 (fr)
KR (1) KR101096357B1 (fr)
CN (2) CN1812793A (fr)
AR (1) AR045893A1 (fr)
AU (1) AU2004251541B2 (fr)
BR (1) BRPI0411882A (fr)
CA (1) CA2529475C (fr)
HK (1) HK1118484A1 (fr)
MX (1) MXPA05014194A (fr)
MY (1) MY145784A (fr)
TW (1) TW200505485A (fr)
WO (1) WO2005000312A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
WO2006059716A1 (fr) * 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited Preparation solide
ZA200805793B (en) * 2005-12-22 2009-11-25 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
WO2007072908A1 (fr) * 2005-12-22 2007-06-28 Otsuka Pharmaceutical Co., Ltd. Méthode pour produire des particules à matrice de cire contenant un médicament, extrudeuse à utiliser dans ladite méthode et préparation à libération prolongée contenant du cilostazol
WO2008103289A1 (fr) * 2007-02-16 2008-08-28 Elevance Renewable Sciences, Inc. Compositions de cire et leurs procédés de fabrication
US8178133B2 (en) 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium compositions and uses thereof
WO2011003045A1 (fr) * 2009-07-01 2011-01-06 Magceutics, Inc. Composition de magnésium à libération lente et ses utilisations
EP2540318B1 (fr) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Préparation solide à libération prolongée pour utilisation orale
EP2540317A4 (fr) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd Préparation solide à libération prolongée pour usage oral
EP2893928B1 (fr) 2012-09-03 2018-10-24 Daiichi Sankyo Company, Limited Composition pharmaceutique à libération prolongée administrée par voie orale contenant du chlorhydrate d'hydromorphone
CN107050023A (zh) * 2017-01-13 2017-08-18 北京顺慈医药科技有限公司 一种盐酸小檗碱的制剂及遮盖药物不良味道的制剂方法
JP7293131B2 (ja) 2017-12-28 2023-06-19 住友ファーマ株式会社 新規微粒子コーティング（薬物含有中空粒子及びその製法）
EP3736297A4 (fr) 2018-01-05 2021-03-24 Toppan Printing Co., Ltd. Particules composites, procédé de production de particules composites, poudre sèche et composition de résine pour moulage
CN112313289A (zh) * 2018-04-27 2021-02-02 凸版印刷株式会社 缓释性复合颗粒、缓释性复合颗粒的制造方法、干燥粉体、以及壁纸
CN108904451A (zh) * 2018-07-27 2018-11-30 广州柏赛罗药业有限公司 缓释制剂
JP6618595B1 (ja) * 2018-10-16 2019-12-11 佐藤薬品工業株式会社 カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法
US20210361581A1 (en) * 2018-10-22 2021-11-25 Ioi Oleo Gmbh Additive for a powder material intended for compaction into shaped bodies
CN114209887B (zh) * 2021-08-24 2023-03-03 杭州协合医疗用品有限公司 一种含可控降解聚酯微球的注射用凝胶
CN113877000B (zh) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 注射用微球组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443846A (en) * 1990-04-28 1995-08-22 Takeda Chemical Industries, Ltd. Granulated preparations and method of producing the same
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
EP0841062A1 (fr) * 1995-07-21 1998-05-13 Daiichi Pharmaceutical Co., Ltd. Preparation granulaire et son procede de production
WO2002096466A1 (fr) * 2001-05-25 2002-12-05 Otsuka Pharmaceutical Co., Ltd. Composition de medicament
WO2003070223A1 (fr) * 2002-02-21 2003-08-28 Otsuka Pharmaceutical Co., Ltd. Preparations a liberation lente et methode de production desdites preparations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3264131A (en) * 1964-05-11 1966-08-02 Polymer Corp Process for fusion coating and materials used therein
JPH0647531B2 (ja) * 1986-02-06 1994-06-22 第一製薬株式会社 徐放性粒状物の製造法
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH03124063A (ja) * 1989-10-06 1991-05-27 Ricoh Co Ltd イメージセンサ
JP3078859B2 (ja) 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
JP2915590B2 (ja) 1991-02-15 1999-07-05 第一製薬株式会社 マスクされた粒状物
JP3130058B2 (ja) * 1991-02-15 2001-01-31 第一製薬株式会社 マスクされた粒状物
US5359170A (en) 1992-02-18 1994-10-25 At&T Global Information Solutions Company Apparatus for bonding external leads of an integrated circuit
JP2949448B2 (ja) 1992-11-30 1999-09-13 ケーヴィ ファーマセチカル カンパニー 味を隠された医薬材料
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
JP3372242B2 (ja) 1999-08-04 2003-01-27 沢井製薬株式会社 徐放性微粒子製剤及びその製造方法
JP2001055342A (ja) * 1999-08-17 2001-02-27 Sakamoto Yakuhin Kogyo Co Ltd 錠剤、錠菓用滑沢剤
CN1202815C (zh) * 1999-08-31 2005-05-25 格吕伦塔尔有限公司 含有曲马朵糖精盐的持续释放给药剂型
US6537671B2 (en) * 2000-12-05 2003-03-25 Alpha Coating Technologies, Llc Coating powders having enhanced electrostatic chargeability
JP2002179571A (ja) 2000-12-11 2002-06-26 Nikken Chem Co Ltd 小型徐放性錠剤
JP2002226304A (ja) 2001-01-31 2002-08-14 Mitsui Chemicals Inc 徐放型微粒子の製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443846A (en) * 1990-04-28 1995-08-22 Takeda Chemical Industries, Ltd. Granulated preparations and method of producing the same
EP0841062A1 (fr) * 1995-07-21 1998-05-13 Daiichi Pharmaceutical Co., Ltd. Preparation granulaire et son procede de production
EP0799616A1 (fr) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Composition orale contenant un dérivé de fumagillol
WO2002096466A1 (fr) * 2001-05-25 2002-12-05 Otsuka Pharmaceutical Co., Ltd. Composition de medicament
WO2003070223A1 (fr) * 2002-02-21 2003-08-28 Otsuka Pharmaceutical Co., Ltd. Preparations a liberation lente et methode de production desdites preparations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKIYAMA Y ET AL: "Novel oral controlled-release microspheres using polyglycerol esters of fatty acids", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 1, 1 July 1993 (1993-07-01), pages 1 - 10, XP023744544, ISSN: 0168-3659, [retrieved on 19930701], DOI: 10.1016/0168-3659(93)90203-H *
See also references of WO2005000312A1 *

Also Published As

Publication number Publication date
CN101219115B (zh) 2012-09-19
BRPI0411882A (pt) 2006-08-29
WO2005000312A1 (fr) 2005-01-06
WO2005000312A8 (fr) 2005-02-24
CN101219115A (zh) 2008-07-16
TW200505485A (en) 2005-02-16
US8734843B2 (en) 2014-05-27
CN1812793A (zh) 2006-08-02
KR101096357B1 (ko) 2011-12-20
CA2529475A1 (fr) 2005-01-06
KR20060026071A (ko) 2006-03-22
AU2004251541B2 (en) 2010-03-04
MY145784A (en) 2012-04-30
AR045893A1 (es) 2005-11-16
US20070098843A1 (en) 2007-05-03
CA2529475C (fr) 2012-08-07
JP4592590B2 (ja) 2010-12-01
TWI333858B (fr) 2010-12-01
AU2004251541A1 (en) 2005-01-06
MXPA05014194A (es) 2006-02-24
JPWO2005000312A1 (ja) 2006-08-03
HK1118484A1 (en) 2009-02-13
EP1640006A1 (fr) 2006-03-29

Similar Documents

Publication Publication Date Title
EP1783096A4 (fr) Poudre de alpha-sialon et procédé servant à produire celle-ci
EP1661856A4 (fr) Graphite en film et son procede de production
AU2003257604A8 (en) Stent and process for producing the same
IL166654A0 (en) Platinum aggregates and process for producing the same
AU2003248074A8 (en) Composite nanoparticle and process for producing the same
HK1092101A1 (en) Fine-grain silver powder and process for producing the same
HK1085489A1 (en) Chitosan-containing polyaccharide, process for producing the same and use thereof
EP1787742A4 (fr) Microparticule de cuivre et procede de fabrication de celle-ci
AU2003293294A8 (en) Uv-stabilised particles
EP1568732A4 (fr) Particules composites fines et leur procede de production
EP1640006A4 (fr) Particules a liberation prolongee de medicament et procede de production de celles-ci
EP1550688A4 (fr) Polysaccharide modifie par un organopolysiloxane et son procede de production
GB2421005B (en) Fibrous laminate and process for producing the same
AU2003264546A1 (en) Photocatalyst material and process for producing the same
HK1087893A1 (en) Masticatable capsule and process for producing the same
EP1651018A4 (fr) Substrat et son procede de production
PL373328A1 (en) Sustained release pharmaceutical prepartations and methods for producing the same
HK1075414A1 (en) Sustained release preparations and process for producing the same
AU2003292763A1 (en) Process for producing microsphere and apparatus for producing the same
EP1544275A4 (fr) Matiere mecanoluminescente et procede de production de celle-ci
EP1699435A4 (fr) Particules
EP1510241A4 (fr) Filtre a electret et procede de production de ce filtre
EP1514870A4 (fr) Promedicament et procede de production de celui-ci
EP1609518A4 (fr) Element filtrant et son procede de production
EP1598372A4 (fr) Composition de particules polymeres et procede permettant de produire ces particules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TOMOHIRA, YUSOFORMULATION RES. INST. OF OTSUKA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120302

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20120227BHEP

Ipc: A61K 9/14 20060101ALI20120227BHEP

Ipc: A61K 47/22 20060101ALI20120227BHEP

Ipc: A61K 47/14 20060101ALI20120227BHEP

Ipc: A61K 47/38 20060101ALI20120227BHEP

Ipc: A61K 9/50 20060101ALI20120227BHEP

17Q First examination report despatched

Effective date: 20120817

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161011